The mechanisms by which CSII achieves protracted glycemic remission in T2D may be the improvement in beta-cell function and insulin resistance1–4, and, may partially, because the positive attitudes towards diabetes by CSII therapy5. The gene discussed is INS; the disease is type 2 diabetes mellitus.